Tvardi Therapeutics is trading at $1.02, down 5.06%, amid biotech weakness and broader risk-off pressure. - No new company-specific announcement explaining the decline was identified; the October 14 conference-participation notice is not a clinical or regulatory milestone. - XBI was down 2.06%. Biotech coverage also describes a recent sector pullback amid rising rates and investor caution. - Current trading volume was not provided.